Join to access to all OVN content. Join for Free
The 2 Most Critical Elements of MSL Territory Excellence with Julie Montiel
MSL territory excellence scientific acumen virtual presentation skills strategic territory planning MSL performance improvement

The 2 Most Critical Elements of MSL Territory Excellence with Julie Montiel


Share This Article


Summary

In this episode, Tom Caravela is joined by Julie Montiel to explore the nuances of MSL territory excellence and the critical role of scientific acumen. They delve into strategies for achieving scientific acumen and crafting effective, individualized territory plans. The conversation highlights the significance of pre-call and post-call planning in managing territories, as well as adapting strategies for virtual and digital engagements. Julie shares tips to enhance virtual presentation skills, concluding with a recap on creating a plan for territory excellence. The episode wraps up with closing remarks on the importance of key MSL strategies and a call to action for listeners.

My guest today is Julie Montiel, the National Scientific Director, Lymphoma/Myeloid MSL at The Janssen. We talk about the two most critical of MSL territory excellence.

In this episode we discuss:

  • Julie’s background
  • The two most critical elements
  • How MSLs improve their performance
  • What is scientific acumen 
  • Why is scientific acumen the most important element of territory excellence
  • What does excellence in scientific acumen look like?
  • Every territory is different
  • Applying principles to a virtual type of scenario
  • How MSLs bring all of these pieces of information together to build strategic territory excellence

Click for Source
MSL territory excellence, scientific acumen, virtual presentation skills, strategic territory planning, MSL performance improvement

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Article
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
OVN Avatar Forbes Books Press Release Official

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Explore OVN